# AET01_AESI Variant 1 works as expected

    Code
      res
    Output
                                                                                       Placebo     Xanomeline High Dose   Xanomeline Low Dose
                                                                                        (N=86)            (N=72)                (N=96)       
      ———————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
      Total number of patients with at least one AE                                   69 (80.2%)        70 (97.2%)            86 (89.6%)     
      Total number of AEs                                                                301               436                    454        
      Total number of patients with at least one AE by worst grade                                                                           
        Grade 1                                                                       22 (25.6%)        18 (25.0%)            19 (19.8%)     
        Grade 2                                                                       24 (27.9%)        19 (26.4%)            35 (36.5%)     
        Grade 3                                                                        8 (9.3%)         16 (22.2%)            11 (11.5%)     
        Grade 4                                                                       12 (14.0%)        16 (22.2%)            19 (19.8%)     
        Grade 5 (fatal outcome)                                                        3 (3.5%)          1 (1.4%)              2 (2.1%)      
      Total number of patients with study drug withdrawn due to AE                        0                 0                      0         
      Total number of patients with dose modified/interrupted due to AE                   0                 0                      0         
      Total number of patients with treatment received for AE                         69 (80.2%)        70 (97.2%)            86 (89.6%)     
      Total number of patients with all non-fatal AEs resolved                         6 (7.0%)          3 (4.2%)              6 (6.2%)      
      Total number of patients with at least one unresolved or ongoing non-fatal AE   63 (73.3%)        67 (93.1%)            80 (83.3%)     
      Total number of patients with at least one serious AE                               0              1 (1.4%)              2 (2.1%)      
      Total number of patients with at least one related AE                               0                 0                      0         

# AET01_AESI Variant 2 works as expected

    Code
      res
    Output
                                                                                          Placebo     Xanomeline High Dose   Xanomeline Low Dose
                                                                                           (N=86)            (N=72)                (N=96)       
      ——————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
      Total number of patients with at least one AE                                      69 (80.2%)        70 (97.2%)            86 (89.6%)     
      Total number of AEs                                                                   301               436                    454        
      Total number of patients with at least one AE by worst grade                                                                              
        Grade 1                                                                          22 (25.6%)        18 (25.0%)            19 (19.8%)     
        Grade 2                                                                          24 (27.9%)        19 (26.4%)            35 (36.5%)     
        Grade 3                                                                           8 (9.3%)         16 (22.2%)            11 (11.5%)     
        Grade 4                                                                          12 (14.0%)        16 (22.2%)            19 (19.8%)     
        Grade 5 (fatal outcome)                                                           3 (3.5%)          1 (1.4%)              2 (2.1%)      
      Total number of patients with study drug withdrawn due to AE                           0                 0                      0         
      Total number of patients with dose modified/interrupted due to AE                      0                 0                      0         
      Total number of patients with treatment received for AE                            69 (80.2%)        70 (97.2%)            86 (89.6%)     
      Total number of patients with all non-fatal AEs resolved                            6 (7.0%)          3 (4.2%)              6 (6.2%)      
        No. of patients with study drug withdrawn due to resolved AE                         0                 0                      0         
        No. of patients with dose modified/interrupted due to resolved AE                    0                 0                      0         
        No. of patients with treatment received for resolved AE                           6 (7.0%)          3 (4.2%)              6 (6.2%)      
      Total number of patients with at least one unresolved or ongoing non-fatal AE      63 (73.3%)        67 (93.1%)            80 (83.3%)     
        No. of patients with study drug withdrawn due to unresolved or ongoing AE            0                 0                      0         
        No. of patients with dose modified/interrupted due to unresolved or ongoing AE       0                 0                      0         
        No. of patients with treatment received for unresolved or ongoing AE             63 (73.3%)        67 (93.1%)            80 (83.3%)     
      Total number of patients with at least one serious AE                                  0              1 (1.4%)              2 (2.1%)      
        No. of patients with study drug withdrawn due to serious AE                          0                 0                      0         
        No. of patients with treatment received for serious AE                               0                 0                      0         
        No. of patients with dose modified/interrupted due to serious AE                     0              1 (1.4%)              2 (2.1%)      
      Total number of patients with at least one related AE                                  0                 0                      0         
        No. of patients with study drug withdrawn due to related AE                          0                 0                      0         
        No. of patients with dose modified/interrupted due to related AE                     0                 0                      0         
        No. of patients with treatment received for related AE                               0                 0                      0         
        No. of patients with serious, related AE                                             0                 0                      0         

# AET01_AESI Variant 3 works as expected

    Code
      res
    Output
                                                                                                            Placebo     Xanomeline High Dose   Xanomeline Low Dose
                                                                                                             (N=86)            (N=72)                (N=96)       
      ————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
      Total number of patients with at least one AE                                                        69 (80.2%)        70 (97.2%)            86 (89.6%)     
      Total number of AEs                                                                                     301               436                    454        
      Total number of patients with at least one AE by worst grade                                                                                                
        Grade 1                                                                                            22 (25.6%)        18 (25.0%)            19 (19.8%)     
        Grade 2                                                                                            24 (27.9%)        19 (26.4%)            35 (36.5%)     
        Grade 3                                                                                             8 (9.3%)         16 (22.2%)            11 (11.5%)     
        Grade 4                                                                                            12 (14.0%)        16 (22.2%)            19 (19.8%)     
        Grade 5 (fatal outcome)                                                                             3 (3.5%)          1 (1.4%)              2 (2.1%)      
      Total number of patients with study drug 1 withdrawn due to AE                                           0                 0                      0         
      Total number of patients with study drug 2 withdrawn due to AE                                           0                 0                      0         
      Total number of patients with dose of study drug 1 modified/interrupted due to AE                        0                 0                      0         
      Total number of patients with dose of study drug 2 modified/interrupted due to AE                        0                 0                      0         
      Total number of patients with treatment received for AE                                              69 (80.2%)        70 (97.2%)            86 (89.6%)     
      Total number of patients with all non-fatal AEs resolved                                              6 (7.0%)          3 (4.2%)              6 (6.2%)      
        No. of patients with study drug 1 withdrawn due to resolved AE                                         0                 0                      0         
        No. of patients with study drug 2 withdrawn due to resolved AE                                         0                 0                      0         
        No. of patients with dose of study drug 1 modified/interrupted due to resolved AE                      0                 0                      0         
        No. of patients with dose of study drug 2 modified/interrupted due to resolved AE                      0                 0                      0         
        No. of patients with treatment received for resolved AE                                             6 (7.0%)          3 (4.2%)              6 (6.2%)      
      Total number of patients with at least one non-fatal unresolved or ongoing AE                        63 (73.3%)        67 (93.1%)            80 (83.3%)     
        No. of patients with study drug 1 withdrawn due to unresolved or ongoing AE                            0                 0                      0         
        No. of patients with study drug 2 withdrawn due to unresolved or ongoing AE                            0                 0                      0         
        No. of patients with dose of study drug 1 modified/interrupted due to unresolved or ongoing AE         0                 0                      0         
        No. of patients with dose of study drug 2 modified/interrupted due to unresolved or ongoing AE         0                 0                      0         
        No. of patients with treatment received for unresolved or ongoing AE                               63 (73.3%)        67 (93.1%)            80 (83.3%)     
      Total number of patients with at least one serious AE                                                    0              1 (1.4%)              2 (2.1%)      
        No. of patients with study drug 1 withdrawn due to serious AE                                          0                 0                      0         
        No. of patients with study drug 2 withdrawn due to serious AE                                          0                 0                      0         
        No. of patients with dose of study drug 1 modified/interrupted due to serious AE                       0                 0                      0         
        No. of patients with dose of study drug 2 modified/interrupted due to serious AE                       0                 0                      0         
        No. of patients with treatment received for serious AE                                                 0              1 (1.4%)              2 (2.1%)      
      Total number of patients with at least one AE related to study drug 1                                    0                 0                      0         
        No. of patients with study drug 1 withdrawn due to AE related to study drug 1                          0                 0                      0         
        No. of patients with study drug 1 withdrawn due to AE related to study drug 2                          0                 0                      0         
        No. of patients with dose of study drug 1 modified/interrupted due to AE related to study drug 1       0                 0                      0         
        No. of patients with dose of study drug 1 modified/interrupted due to AE related to study drug 2       0                 0                      0         
        No. of patients with treatment received for AE related to study drug 1                                 0                 0                      0         
        No. of patients with serious AE related to study drug 1                                                0                 0                      0         
      Total number of patients with at least one AE related to study drug 2                                    0                 0                      0         
        No. of patients with study drug 2 withdrawn due to AE related to study drug 1                          0                 0                      0         
        No. of patients with study drug 2 withdrawn due to AE related to study drug 2                          0                 0                      0         
        No. of patients with dose of study drug 2 modified/interrupted due to AE related to study drug 1       0                 0                      0         
        No. of patients with dose of study drug 2 modified/interrupted due to AE related to study drug 2       0                 0                      0         
        No. of patients with treatment received for AE related to study drug 2                                 0                 0                      0         
        No. of patients with serious AE related to study drug 2                                                0                 0                      0         

# AET01_AESI Variant 4 works as expected

    Code
      res
    Output
                                                                                        Placebo    Xanomeline High Dose   Xanomeline Low Dose
      Standardized MedDRA Query                                                          (N=86)           (N=72)                (N=96)       
      ———————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
      SMQ01 (BROAD)                                                                                                                          
        Total number of patients with at least one AE                                   4 (4.7%)        10 (13.9%)             6 (6.2%)      
        Total number of AEs                                                                6                21                    10         
        Total number of patients with at least one AE by worst grade                                                                         
          Grade 1                                                                       1 (1.2%)         5 (6.9%)              3 (3.1%)      
          Grade 2                                                                       2 (2.3%)         2 (2.8%)              2 (2.1%)      
          Grade 3                                                                          0             2 (2.8%)                  0         
          Grade 4                                                                          0                0                  1 (1.0%)      
          Grade 5 (fatal outcome)                                                       1 (1.2%)         1 (1.4%)                  0         
        Total number of patients with study drug withdrawn due to AE                       0                0                      0         
        Total number of patients with dose modified/interrupted due to AE                  0                0                      0         
        Total number of patients with treatment received for AE                         4 (4.7%)        10 (13.9%)             6 (6.2%)      
        Total number of patients with all non-fatal AEs resolved                        3 (3.5%)         4 (5.6%)              3 (3.1%)      
        Total number of patients with at least one non-fatal unresolved or ongoing AE   1 (1.2%)         6 (8.3%)              3 (3.1%)      
        Total number of patients with at least one serious AE                              0                0                      0         
        Total number of patients with at least one related AE                              0                0                      0         
      SMQ02 (NARROW)                                                                                                                         
        Total number of patients with at least one AE                                   3 (3.5%)         5 (6.9%)              6 (6.2%)      
        Total number of AEs                                                                4                8                     13         
        Total number of patients with at least one AE by worst grade                                                                         
          Grade 1                                                                       1 (1.2%)         3 (4.2%)              3 (3.1%)      
          Grade 2                                                                       2 (2.3%)         2 (2.8%)              1 (1.0%)      
          Grade 3                                                                          0                0                      0         
          Grade 4                                                                          0                0                  1 (1.0%)      
          Grade 5 (fatal outcome)                                                          0                0                  1 (1.0%)      
        Total number of patients with study drug withdrawn due to AE                       0                0                      0         
        Total number of patients with dose modified/interrupted due to AE                  0                0                      0         
        Total number of patients with treatment received for AE                         3 (3.5%)         5 (6.9%)              6 (6.2%)      
        Total number of patients with all non-fatal AEs resolved                           0                0                  1 (1.0%)      
        Total number of patients with at least one non-fatal unresolved or ongoing AE   3 (3.5%)         5 (6.9%)              5 (5.2%)      
        Total number of patients with at least one serious AE                              0                0                      0         
        Total number of patients with at least one related AE                              0                0                      0         
      CQ01                                                                                                                                   
        Total number of patients with at least one AE                                   7 (8.1%)         6 (8.3%)              3 (3.1%)      
        Total number of AEs                                                                8                9                      4         
        Total number of patients with at least one AE by worst grade                                                                         
          Grade 1                                                                       5 (5.8%)         3 (4.2%)              2 (2.1%)      
          Grade 2                                                                       1 (1.2%)         3 (4.2%)              1 (1.0%)      
          Grade 3                                                                          0                0                      0         
          Grade 4                                                                       1 (1.2%)            0                      0         
          Grade 5 (fatal outcome)                                                          0                0                      0         
        Total number of patients with study drug withdrawn due to AE                       0                0                      0         
        Total number of patients with dose modified/interrupted due to AE                  0                0                      0         
        Total number of patients with treatment received for AE                         7 (8.1%)         6 (8.3%)              3 (3.1%)      
        Total number of patients with all non-fatal AEs resolved                        1 (1.2%)         2 (2.8%)              2 (2.1%)      
        Total number of patients with at least one non-fatal unresolved or ongoing AE   6 (7.0%)         4 (5.6%)              1 (1.0%)      
        Total number of patients with at least one serious AE                              0                0                      0         
        Total number of patients with at least one related AE                              0                0                      0         

